We studied the effects of 3-[3-hexyloxy-1,2,5-thiadiazo-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) wash-resistant binding on presynaptic muscarinic regulation of electrically evoked [
polamine during 100 M xanomeline treatment nor previous irreversible inactivation of the classical receptor binding site using propylbenzylcholine mustard in cortical slices prevented the inhibitory effect of wash-resistantly bound xanomeline. Treatment of cortical slices with xanomeline slightly decreased the number of muscarinic binding sites, and it markedly decreased affinity for N-methylscopolamine. When applied as in acetylcholine release experiments, xanomeline did not impair presynaptic ␣ 2 -adrenoceptor-mediated regulation of noradrenaline release. The functional studies in brain tissue reported in this work demonstrate that xanomeline can function as a washresistant agonist of native presynaptic muscarinic M 2 and M 4 receptors with both competitive and allosteric components of action.
3-[3-Hexyloxy-1,2,5-thiadiazo-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) is an atypical agonist that binds to all muscarinic receptor subtypes with high affinity (Bymaster et al., 1997; Watson et al., 1998; Wood et al., 1999; Jakubík et al., 2006) , but it displays functional selectivity for the M 1 and M 4 receptors (Shannon et al., 1994; Ward et al., 1995; Bymaster et al., 1997 Bymaster et al., , 1998 . Xanomeline was supposed to be developed as an M 1 receptor-selective drug for treatment of Alzheimer's disease. However, original clinical trials revealed frequent peripheral side effects that were not consistent with M 1 selectivity and led to interruption of testing (Mirza et al., 2003) . More recent behavioral studies in rodents, primates, and clinical studies have pointed to potential profitable antipsychotic effects that are ascribed to the M 1 /M 4 agonistic profile of the drug (Bymaster et al., 2002; Andersen et al., 2003) .
We observed previously that xanomeline interacts with two binding sites on the muscarinic receptor, i.e., the orthosteric binding site and another distinct site where it binds in a wash-resistant manner (Christopoulos et al., 1998; Jakubík et al., 2002 Jakubík et al., , 2004 . Wash-resistantly bound xanomeline activates guanosine 5Ј-O-(3-thio)triphosphate binding at the M 1 receptor, and, although with lower efficacy but similar affinity, also at the M 2 receptor (Jakubík et al., 2006) . Likewise, wash-resistantly bound xanomeline induces durable antagonism of M 5 receptor activation (Grant and El-Fakahany, 2005) . Together, these findings strongly indicate that the complicated pharmacological profile of xanomeline action may be due not only to the selective stimulation of M 1 /M 4 receptors but also to not yet well characterized effects of wash-resistant xanomeline at all subtypes of muscarinic receptors thus far tested.
All these observations on the effects of wash-resistant xa- Fig. 1 . Immediate application of xanomeline does not influence electrically evoked [ 3 H]ACh release and its presynaptic M 2 (cortex) and M 4 (striatum) receptor-mediated inhibition. Brain cortical (left column) and striatal (right column) slices were stimulated (2-ms monopolar pulses at 1 Hz for 1 min at 25 mA) at the beginning of the 3rd, 9th, and 15th collection fraction (abscissa). A and D, no drug (closed circles) or 10 M xanomeline (open circles) was present 4 min before and during the second stimulation and 10 M NMS 4 min before and during the third stimulation as indicated. [
3 H]ACh release is expressed as fractional release in percentage of tissue content of radioactivity (ordinate). B and E, slices were stimulated as in described in previous experiments but in the presence of 10 M carbachol (closed squares) or 10 M carbachol and 10 M xanomeline together during the second stimulation. Points are mean Ϯ S.E.M. of five to nine samples from two (cortex) or three (striatum) animals in independent experiments. Ordinate, fractional release of radioactivity. Abscissa, time from the end of loading. C and F, influence of tested drugs is expressed (ordinate) as S n /S 1 ratios (relative to the first, always control, stimulation; letters Ct, x, c, and cx denote superfusion with control medium, 10 M xanomeline, 10 M carbachol, or 10 M xanomeline and 10 M carbachol together before and during the second stimulation, respectively). ‫,ءء‬ p Ͻ 0.01, significantly different from corresponding preceding control stimulation and following stimulation in the presence of 1 M NMS by ANOVA followed by Tukey's test.
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at ASPET Journals on May 28, 2017 jpet.aspetjournals.org nomeline on receptor function were derived in experiments on human muscarinic receptors heterologously expressed in fibroblasts (Chinese hamster ovary cells). It is therefore very important to elucidate whether such unusual effects of xanomeline are also evident in case of receptors expressed in their natural environment. To approach this question, we performed ex vivo experiments with rat brain cortical and striatal tissue. We investigated delayed wash-resistant effects of xanomeline on the regulation of stimulation-evoked release of acetylcholine (ACh) that is mediated by M 2 receptors in brain cortex and M 4 receptors in striatum (Doležal and Tuček, 1998; Zhang et al., 2002; Bymaster et al., 2003) . We show that wash-resistant xanomeline binding decreases evoked ACh release by stimulating both M 2 and M 4 receptors and that both the allosteric and orthosteric binding sites participate in this effect.
Materials and Methods
Release Experiments. Brain cortical and striatal prisms were prepared from 2-to 3-month-old male Wistar rats using a McIlwain tissue chopper set at a width of 0.35 mm. Superfusion experiments were done essentially as described previously (Lazareno et al., 2004) . In brief, brain cortical slices were loaded with [ 3 H]choline (specific radioactivity, 82 Ci/mmol; Amersham, Little Chalfont, Buckinghamshire, UK) in Krebs' buffer (138 mM NaCl, 3 mM KCl, 1.2 mM CaCl 2 , 1 mM MgCl 2 1, 1.2 mM NaH 2 PO 4 , 25 mM NaHCO 3 , and 10 mM glucose; for noradrenaline release experiments in addition 0.03 mM EDTA and 0.06 mM ascorbic acid) for 30 min. Superfusion medium contained 10 M hemicholinium-3 in ACh release experiments to prevent reuptake of labeled choline, and 1 M desipramine was added in noradrenaline release experiments to prevent reuptake of labeled noradrenaline. Domperidone (500 nM) was included to prevent dopamine D 2 receptor-mediated inhibition of acetylcholine release ( (Doležal et al., 1992) . The release was evoked electrically by applying 60 2-ms rectangular monopolar pulses (1 Hz; 25 mA) at the beginning of the 3rd, 9th, and 15th 4-min fraction denoted S 1 , S 2 , and S 3 , respectively. Immediate effects of tested drugs were determined by adding them to the superfusion medium 8 min before respective stimulation. Tested drugs remained in the medium as indicated in the figures. Effects of wash-resistantly bound xanomeline were studied in experiments in which brain prisms were preincubated for 15 min in the presence of 1 to 100 M xanomeline, thoroughly washed with fresh medium, and superfused using xanomeline-free medium for 53 min before the first electrical stimulation. In some experiments, 100 nM propylbenzylcholine mustard (PRBCM) was added during the last 15 min of loading with [ 3 H]choline to irreversibly inactivate muscarinic receptor orthosteric binding sites (Fig. 5B) . Selectivity of xanomeline pretreatment on regulation of acetylcholine release was verified in analogous experiments after loading tissue with [ 3 H]noradrenaline (specific radioactivity, 36 Ci/mmol; Amersham) and evaluating functionality of the ␣ 2 -adrenoceptor-mediated presynaptic inhibition of noradrenaline release.
The evoked release of tritiated ACh and noradrenaline is expressed as fraction of tissue content of radioactivity present at the beginning of individual collected fractions during a 4-min collection period over background. Jakubík et al. (2006) . Curve fitting and statistical evaluation of data were done using Prism 4 (GraphPad Software Inc., San Diego, CA).
Chemicals. Xanomeline was kindly supplied by Dr. C. Felder (Eli Lilly & Co., Indianapolis, IN). Hemicholinium-3, carbachol, N-methylscopolamine (NMS), desipramine, UK-14,304, domperidone, and yohimbine were from Sigma (Prague, Czech Republic), and PRBCM was from NEN (Boston, MA). All other chemicals were of highest available purity.
All experiments were performed on male albino Wistar rats bred in the animal house of the Institute of Physiology (Czech Academy of Sciences, Prague, Czech Republic). The experiments were approved by the Animal Care and Use Committee of the Institute of Physiology to be in agreement with the Animal Protection Law of the Czech Republic that is fully compatible with European Community Council directives 86/609/EEC.
Results
In control slices, sequential stimulations applied at the 9th and 33rd min of superfusion (third and ninth collected fractions) evoked the release of [ 3 H]ACh that slightly declined from 0.92 Ϯ 0.08 to 0.78 Ϯ 0.06% of tissue content of radioactivity (mean Ϯ S.E.M.; n ϭ 6) in cortex and from 2.99 Ϯ 0.44 to 2.53 Ϯ 0.41 (n ϭ 9) in striatum ( Fig. 1, A and D) . Addition of 10 M xanomeline to the superfusion medium had no effect on either basal outflow of radioactivity (0.85 Ϯ 0.04 versus 0.80 Ϯ 0.02% of tissue content of radioactivity in cortex and 1.13 Ϯ 0.07 versus 1.11 Ϯ 0.18 in striatum for control and xanomeline treatments, respectively) or electrically evoked release of Xanomeline at a concentration of 10 M present together with carbachol did not influence its inhibitory effect (Fig. 1, B and C, for cortex and E and F, for striatum).
Pretreatment of choline-loaded cortical and striatal slices with 1, 10, or 100 M xanomeline for 15 min followed by extensive washing had no effect on basal outflow of radioactivity, but it resulted in a concentration- Binding experiments with membranes of CHO cells expressing human M 1 -M 5 subtypes of muscarinic receptors demonstrated that wash-resistant xanomeline binding occurs with similar potency at all subtypes (Fig. 3) . Likewise, pretreatment of cortical slices with 100 M xanomeline followed by washing as in superfusion experiments slightly decreased maximal binding of [ 3 H]NMS determined in corti- Table 2 ).
In the next experiments, we further investigated features of the irreversible agonistic effects of pretreatment with 100 M xanomeline in cortical slices, i.e., at M 2 receptors. As shown in Fig. 4A and Table 3 , the release of acetylcholine after xanomeline pretreatment was stable for at least three stimulations. Neither presence of 1 M NMS during xanomeline treatment ( Fig. 4B; Table 3 ) nor continuous washing with 1 M NMS for 57 min before stimulation ( Fig. 4C ; Table  3 ) prevented inhibition of ACh release. In experiments summarized in Fig. 5, A Fig. 5A ; Table 4 ). The small remaining response to carbachol was not receptor-mediated, because it was not blocked by NMS. However, in line with our observation that NMS present together with xanomeline does not prevent its delayed inhibitory effects on ACh release, preincubation of PRBCM-treated slices with 100 M xanomeline for 15 min still strongly inhibited ACh release, and this inhibition was not reversed in the presence of NMS during stimulation, contrary to what is expected in case of drugs acting through the orthosteric binding site.
Discussion
Xanomeline is a muscarinic agonist that binds equally well to all subtypes of muscarinic receptors, but its immediate application in functional assays in vitro points to M 1 /M 4 selectivity (Bymaster et al., 1997) . Another remarkable feature of xanomeline interaction with muscarinic receptors is its wash-resistant binding demonstrated at M 1 (Christopoulos et al., 1998 (Christopoulos et al., , 1999 Jakubík et al., 2002 Jakubík et al., , 2004 , M 2 (Jakubík et al., 2006) , and M 5 (Grant and El-Fakahany, 2005) receptors. We also demonstrate wash-resistant binding of xanomeline to the M 3 and M 4 receptor subtypes that has similar affinity with other subtypes (Fig. 3) . In addition, it has been demonstrated that in the absence of free ligand, wash-resistantly bound xanomeline exhibits different potency, time course, and efficacy in activating M 1 and M 2 receptors (Jakubík et al., 2006) and antagonizes the M 5 subtype (Grant and El-Fakahany, 2005) . However, all these observations were obtained using muscarinic receptors heterogenously expressed in cell lines. The main finding of the present experiments is the confirmation of the presence of persistent washresistant effects of xanomeline at M 2 and M 4 receptors expressed in their natural environment.
In line with previous findings on M 2 receptors expressed in membranes of CHO cells, xanomeline at concentrations that saturate the orthosteric binding site had no immediate effect on either basal efflux of radioactivity or evoked release of labeled ACh release from cortical slices. Conversely, preincubation of cortical slices for 15 min with xanomeline induced a delayed concentration-dependent decrease of evoked ACh release estimated 53 min after xanomeline washout. The half-maximal inhibition of evoked ACh release by wash-resistant xanomeline was reached at around 1 M. The maximal effect of xanomeline amounted to that of the full agonist carbachol and maximal effects of xanomeline and carbachol were not additive, indicating common mechanism of action, i.e., activation of M 2 receptors. Although the potency of washresistant xanomeline in inhibiting ACh release and in inducing coupling of M 2 receptor expressed in CHO cell membranes to G i/o G proteins (Jakubík et al., 2006 ) is reasonably comparable, its efficacy in inhibiting evoked acetylcholine release is higher. This discrepancy may be due to receptor reserve of autoreceptors on cholinergic endings.
Selectivity of xanomeline pretreatment with regard to muscarinic receptor-mediated effects was tested using presynaptic ␣ 2 -adrenoceptors that mediate presynaptic inhibition of evoked noradrenaline release (Starke, 2001 ). Noradrenaline release from rat brain cortex in vivo is not influenced by administration of xanomeline (Perry et al., 2001 ). In concert, as shown in Fig. 2C and Table 1 , xanomeline pretreatment at concentrations up to 10 M had no appreciable effect on evoked noradrenaline release or on its inhibition by the ␣ 2 -adrenoceptor agonist UK-14,304. Pretreatment with 100 M xanomeline, however, significantly increased basal outflow of radioactivity and somehow reduced evoked noradrenaline release. However, the inhibition of evoked release by an ␣ 2 -adrenergic agonist remained preserved.
An interesting feature of wash-resistant xanomeline inhibitory action was observed in experiments testing the involvement of the orthosteric site in xanomeline effects on ACh release. Presence of the orthosteric antagonist N-methylscopolamine in the medium during stimulation abolishes inhibition of ACh release observed after treatment with low concentrations of xanomeline (1 and 10 M), whereas only partial prevention was found after treatment with 100 M xanomeline for both cortex and striatum. The inhibition of ACh release from cortical slices induced by pretreatment with 100 M xanomeline was not abolished by either presence of N-methylscopolamine during pretreatment or extensive washing in the presence of N-methylscopolamine. Like- (6) wise, irreversible inactivation of the orthosteric binding site using propylbenzylcholine mustard before xanomeline treatment reduced [ 3 H]N-methylscopolamine binding by more than 95% and abolished carbachol-induced inhibition of evoked ACh release, but it did not prevent the inhibitory action of wash-resistantly bound xanomeline. These results apparently indicate that binding of xanomeline to the orthosteric site is not imperative for formation of its wash-resistant interaction with the receptor. Furthermore, they demonstrate that wash-resistant xanomeline activates the receptor even when the orthosteric site is obstructed as evidenced by abolition of N-methylscopolamine binding and inhibition of evoked ACh release by an orthosteric agonist after propylbenzylcholine treatment.
The inhibitory action of xanomeline on ACh release was similar in cortex and striatum in that it did not display immediate effects; the concentration-responses were roughly the same, in line with comparable affinity of wash-resistant binding (Fig. 3) ; and the delayed inhibitory effects were not prevented by pretreatment with xanomeline in the presence of antagonist (data not shown for striatum). This observation was a bit surprising in striatum because of reported M 1 /M 4 agonistic profile (Bymaster et al., 2002 . Because striatum contains cholinergic interneurons, we verified that the inhibitory action of xanomeline on ACh release was effected through presynaptic M 4 receptors in experiments with 50 mM potassium stimulation that precludes a possible involvement of action potential propagation from cell bodies. As with electrical stimulation, xanomeline had no immediate effect when applied 8 min before and during potassium stimulation. However, preincubation with 100 M xanomeline for 15 min followed by 53-min washing significantly reduced evoked ACh release (data not shown). We speculate that wash-resistant xanomeline binding is necessary for agonistic effects of xanomeline. It may be a matter of kinetics of wash-resistant binding formation that is very fast in M 1 receptor; therefore, receptor activation seems immediately. This is in contrast to much slower onset in case of the M 2 subtype (Jakubík et al., 2006) and perhaps also in the M 4 subtype. Alternatively, free xanomeline acting only through the orthosteric binding site might have antagonistic effects. This possibility is unlikely because continuous presence of xanomeline does not interfere with carbachol inhibitory influence on ACh release (Fig. 1, B and E). Moreover, we did not observe a reduction of washresistant xanomeline-induced receptor activation by free xanomeline in M 1 and M 2 receptors (Jakubík et al., 2006) .
In conclusion, results of our experiments demonstrate wash-resistant delayed agonistic effects of xanomeline at muscarinic M 2 and M 4 receptors in functional tests using natural brain tissue. They are in line with observations obtained in binding and functional experiments in CHO cells expressing individual subtypes of muscarinic receptors, and they provide evidence for a complex mode of xanomeline action that encompasses both orthosteric and allosteric components. Interaction of xanomeline at an allosteric site on the muscarinic receptor is probably involved in its wash-resistant binding and agonistic effects (Jakubík et al., 2002) . Thus, our findings support the potential of allosteric agonists (Lazareno and Birdsall, 1995; Jakubík et al., 1996 Jakubík et al., , 1998 Jakubík et al., , 2006 Sur et al., 2003; Langmead et al., 2006) , and they provide an example of an agonist drug with prolonged activity that lingers in the absence of free ligand. 
